At AMA Medical Group, we provide testing, vaccination, and preventative care for COVID-19 patients. One of the latest innovative treatment options, available under the guidance of Dr. Cruz Faña-Souchet, our seasoned and board-certified infectious disease leader and founder, is Regeneron monoclonal antibody therapy for eligible patients.
Monoclonal antibodies are made in a lab and given to people directly through an IV, designed to fight infection in the same way as the antibodies our bodies naturally make.
In clinical trials, Regeneron monoclonal antibodies produced two primary results:
- Reduced hospitalization or ER visits for high-risk patients
- Faster recovery times from COVID-19
Regeneron monoclonal antibodies are intended for patients who have developed COVID-19 symptoms within the past 10 days and are at a high risk for developing a severe case of the disease because of factors such as diabetes, heart disease or obesity. In order to qualify to receive the treatment, the patient must not be hospitalized or be receiving oxygen treatment.
If you think you may qualify for monoclonal antibody treatment and want to ask about getting treatment, contact us today.
